Trial Profile
Clinical trial of nivolumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck cancer after six months who finished platinum-based chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Aug 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 20 Aug 2022 Status changed from active, no longer recruiting to completed.
- 18 Feb 2021 Status changed from recruiting to active, no longer recruiting.
- 20 Feb 2018 New trial record